Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/26073
Başlık: Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C
Yazarlar: Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Gastroenteroloji Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.
Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.
0000-0003-2467-9356
0000-0003-0463-6818
0000-0003-4518-5283
0000-0002-3208-6211
0000-0003-4526-4352
Yılmaz, Yusuf
Dolar, Enver
Ulukaya, Engin
Akgöz, Semra
Keskin, Murat
Kıyıcı, Murat
Yerci, Ömer
Oral, Arzu Yılmaztepe
Gül, Cuma Bülent
Gürel, Selim
Nak, Selim Giray
Gülten, Macit
A-7063-2018
AAG-9177-2021
AAI-4213-2021
A-5841-2017
K-5792-2018
K-6651-2012
22936014300
6602075084
6602927353
14061863400
23050640000
6507627491
6603810549
23091316500
23988796000
7003706434
6603336505
6603629209
Anahtar kelimeler: Apoptosis
Biomarker
Chronic hepatitis C
Histopathology
Nonalcoholic steatohepatitis
Fatty liver-disease
Extracellular cytokeratin-18
Scoring system
Soluble forms
Apoptosis
Expression
Steatosis
Research & experimental medicine
Yayın Tarihi: Nis-2009
Yayıncı: Int Scientific Literature
Atıf: Yılmaz, Y. vd. (2009). "Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C". Medical Science Monitor, 15(4), CR189-CR193.
Özet: Background: Caspase-cleaved cytokeratin 18 (CK18-Asp396) is released from hepatocytes during apoptosis. Recent studies have indicated that serum levels of CK18-Asp396 could be clinically useful biomarker of chronic liver disease. To shed more light on the rate of hepatocyte loss by apoptosis in chronic liver disease, serum levels of CK18-Asp396 were examined in patients with nonalcoholic steatohepatitis (NASH) and chronic hepatitis C. Material/Methods: Apoptotic CK18-Asp396 levels were quantified in sera from 35 patients with nonalcoholic steato-hepatitis (NASH), 21 patients with chronic hepatitis C (HCV), and 18 healthy controls. Results: Analysis of serum CK18-Asp396 levels showed an increasing trend starting from healthy controls (median: 34.5 U/l), to HCV patients (80.1 U/l), to patients with NASH (144.1 U/l. Kruskall-Wallis test: P<0.001). Post hoc analyses revealed that CK18-Asp396 levels were significantly higher in the NASH patients than in both HCV patients (P=0.008) and healthy controls (P<0.001). Moreover, the levels were significantly higher in patients with HCV than in control individuals (P<0.05). In patients with chronic HCV infection there was a significant positive correlation between serum CK18-Asp396 levels and AST (r=0.442, p<0.05), the ultrasonographic grade of steatosis (r = 0.446, P<0.05), and the histological steatosis score (r=0.759, P<0.001). Conclusions: Although subject to future confirmation, these pilot findings seem to indicate that serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) are higher in patients with NASH than in those with chronic HCV infection. These data suggest that NASH patients have and increased hepatocyte loss by apoptosis compared with chronic hepatitis C patients.
URI: http://hdl.handle.net/11452/26073
ISSN: 1234-1010
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.